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Opioids are essential to the management of pain in many patients, but they also are associated with
potential risks for abuse, overdose, and diversion. A number of efforts have been devoted to the
development of abuse-deterrent formulations of opioids to reduce these risks. This article
summarizes a consensus meeting that was organized to propose recommendations for the types of
clinical studies that can be used to assess the abuse deterrence of different opioid formulations.
Due to the many types of individuals who may be exposed to opioids, an opioid formulation will
need to be studied in several populations using various study designs in order to determine its
abuse-deterrent capabilities. It is recommended that the research conducted to evaluate abuse
deterrence should include studies assessing: (1) abuse liability; (2) the likelihood that opioid
abusers will find methods to circumvent the deterrent properties of the formulation; (3) measures
of misuse and abuse in randomized clinical trials involving pain patients with both low risk and
high risk of abuse; and (4) post-marketing epidemiological studies.
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1. Introduction
The number of prescriptions for opioid analgesics has increased substantially over the past
decade [39,51]. In the United States, opioid analgesics were the most commonly prescribed
medications in 2009, accounting for 202 million prescriptions [71]. Coinciding with the
increasing use of opioids, prescription opioid abuse has become a significant public health
problem [20,23,28]. In 2010, there were 2 million new initiates to nonmedical use of
prescription opioids in the United States, a number that surpassed all other substances of
abuse with the exception of marijuana [63]. Along with the increase in prescription opioid
abuse, there have been substantial increases in the number of substance abuse treatment
admissions for addiction to prescription opioids [64] and in the number of prescription
opioid-related emergency department visits and overdose deaths [39].
Chronic pain and opioid addiction are clearly interrelated, though many facets of the
relationship have been incompletely defined. The percentages of chronic pain patients who
develop opioid abuse after being prescribed opioids are uncertain, but estimates have ranged
from less than 1% to more than 18% [34,35] and may be substantially higher in vulnerable
populations [65]. Some investigators have found evidence of aberrant drug-related behavior
in more than 40% of patients when assessed by urine toxicology screen with [48] or without
[72] behavioral monitoring. At the same time, the prevalence of chronic pain is high among
individuals with opioid addiction [73]; for example, in a study of 248 methadone
maintenance patients, 61% reported chronic pain [42]. A personal history of drug or alcohol
abuse and a family history of substance abuse appear to be predictors of aberrant drug-
related behavior, but there remains a paucity of good evidence to guide providers in the
prediction of which patients with pain will develop aberrant drug taking behavior in
response to receiving prescription opioids and also in the management of pain in patients at
increased risk of aberrant drug taking behavior [19,68].
The development of abuse-deterrent formulations (ADF) of opioid analgesics should
theoretically allow treatment of pain while reducing the rate of prescription opioid abuse and
related adverse outcomes [44]. An ADF might present a public health advantage if it
reduced the likelihood of: (1) pain patients progressing to opioid abuse or addiction; (2)
recreational users escalating their abuse and developing addiction; (3) established
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individuals with addiction developing complications related to their condition; or (4)
reducing accidental ingestion or overdose-related morbidity and mortality. Unfortunately, an
opioid formulation may reduce the likelihood of one of these outcomes while
simultaneously producing unintended adverse effects within another population. For
example, many clinicians and investigators initially thought that sustained-release
oxycodone would be relatively abuse-deterrent because its slower onset and longer duration
of action would produce less euphoria (which is thought to promote addiction) than
immediate-release oxycodone. However, sustained-release oxycodone became a widely
abused prescription drug after entering the market, at least in part because the sustained-
release mechanism can be circumvented by crushing the tablet (resulting in a rapid release
of drug and subsequent powerful euphoric effect) [20]. The potential for such unintended
consequences suggests that rigorous testing using a variety of research designs and subject
populations is necessary to evaluate the abuse deterrence of an opioid analgesic formulation
adequately.
2. Methods
In June 2009, the Initiative on Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT), a consortium representing academia, governmental agencies (e.g., Food
and Drug Administration [FDA], National Institute on Drug Abuse, and Substance Abuse
and Mental Health Services Administration), pharmaceutical companies, and patient
advocacy and research organizations, convened a two-day consensus meeting with the aim
of developing consensus recommendations for the types of clinical studies that would be
needed to assess the abuse deterrence of opioid analgesic formulations. Participants were
selected for their expertise in research, administration, or clinical care related to opioid
abuse, or in clinical research and treatment involving chronic pain. The consensus meeting
was designed to reflect broad representation of relevant disciplines and perspectives while
limiting the size in order to promote fruitful and efficient discussion.
A set of background articles was circulated prior to the meeting [1,5,19,21,28,44,55]. In
addition, lectures were presented covering the scope of opioid abuse (R. Denisco), pre-
clinical and clinical research design issues (E. Adams, S. Comer, N. Dasgupta, N. Katz, M.
Klein, D. Leiderman, J. Zacny), and epidemiologic approaches (J. Brownstein, R. Dart).
3. General issues
Several different types of ADFs of opioid analgesics have been or are currently being
developed with the potential to reduce abuse without affecting analgesia (see examples in
Table 1). Typically, these methods have been designed to deter the risk of tampering by
those seeking to abuse the medication, rather than reducing the risk of developing abuse or
addiction among patients who had been taking the medication as prescribed; however, it is
possible that reducing tampering might decrease progression to abuse or addiction.
The best evidence that an opioid formulation is truly abuse deterrent would be the
demonstration that, after adjusting for potential confounders, the total rate of prescription
opioid abuse declined substantially after prescriptions for the ADF largely replaced other
prescription opioids available [10,44,55]. Such data could only be collected after a
formulation has become available and only if the formulation essentially replaces other
forms of prescription opioids available. Evidence that a specific ADF is not abused after its
use becomes established would also be compelling. Because epidemiologic data only
become available after approval and marketing of the formulation, other methods would
need to be used to determine whether a formulation is likely to have a lower risk of abuse
than alternative prescription opioids before it becomes available.
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As described below, there are numerous considerations related to the design of a study that
seeks to assess the abuse liability of an opioid formulation. Fundamentally, the central aims
of the study must be clearly identified, and these will affect the choice of the best study
population and study design. Each of the study designs described below has strengths and
limitations, and these must be carefully weighed when selecting among them to address
specific questions and when results of the studies are interpreted. Since each study will, by
necessity, be designed to answer only very specific questions in selected populations, the
overall abuse liability of an opioid formulation will be best established by evaluating the
results of a number of complementary studies employing varied methods and different
populations.
3.1. Definitions
One challenge in interpreting the literature is the lack of uniform definitions of abuse-related
terms among investigators, regulators, and clinicians [18]. In order to maintain consistency
throughout the meeting, the definitions of abuse and misuse that were developed by a
previous panel of experts were used. Specifically, misuse was considered “use of a
medication (for a medical purpose) other than as directed or indicated, whether willful or
unintentional, and whether harm results or not,” and abuse was considered “any use of an
illegal drug or the intentional self-administration of a medication for a nonmedical purpose
such as altering one’s state of consciousness, for example, getting high” [45].
A distinction should be made regarding the level of evidence available that a medication
formulation is truly abuse-deterrent. We will use the term “putative abuse-deterrent
formulation” (pADF) to refer to a formulation that has a theoretical basis for potentially
being abuse-deterrent. The term “likely abuse-deterrent formulation” (lADF) will be used to
refer to a formulation for which there is a body of evidence from clinical trials and other
research but not epidemiologic studies suggesting that the formulation may be abuse-
deterrent. Methods of evaluating the likelihood that a formulation is genuinely abuse-
deterrent are described below. Finally, we reserve the use of ADF for formulations that have
been shown to be lADFs and to actually reduce abuse relative to other opioid analgesics in
high-quality epidemiologic studies, possibly supplemented by results of large-scale clinical
trials in chronic pain patients with abuse endpoints.
The level of evidence required by the medical and scientific communities for a formulation
to be considered an lADF rather than a pADF is difficult to specify. In general, it is
recommended that the results of a mosaic of studies be evaluated before a pADF can be
considered likely to be abuse-deterrent (i.e., lADF), and that individual formulations will
need to be considered on a case-by-case basis incorporating careful consideration of the
features of the formulation, and the number, types, and quality of the studies supporting
abuse deterrence. This research should include studies assessing: (1) the “likability” of the
formulation; (2) the likelihood that opioid abusers will find methods to circumvent the
abuse-deterrent properties and make the formulation highly abusable (e.g., identifying
methods to convert the opioid into an injectable or inhalable form); (3) misuse or abuse
outcomes in randomized clinical trials (RCTs) involving pain patients with both low and
higher risk of abuse; and, if possible, (4) epidemiological data. These distinctions are
intended to be considered and balanced with other available information regarding the
formulation.
3.2. Choice of comparator
A pADF purports to be abuse-deterrent relative to existing formulations. Studies intending
to demonstrate abuse deterrence will generally need to compare the pADF to comparable
dosages of the most similar existing formulation of the opioid (e.g., if a pADF is developed
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for an extended-release formulation of an opioid, the pADF would typically be compared
with the nonADF extended-release formulation of the opioid). If no existing formulation
exists, such as with a new molecular entity, comparisons with a well-characterized opioid-
agonist at what are likely to be equianalgesic dosages can be conducted [76]. Biased dosing,
such as lower dosing of the pADF relative to the standard formulation, must be avoided, as
abuse liability relates not just to the formulation but also to the dosage. Longer-acting
opioids will generally require higher dosages administered less frequently in clinical
scenarios to produce plasma concentrations that are comparable to short-acting opioid
formulations administered more frequently (i.e., the total mg administered in 24 hours
should be comparable). In some circumstances, additional comparison with other opioids or
pADFs may be useful for demonstrating the relative abuse deterrence of different treatment
options, but these should supplement rather than replace comparison with the standard
opioid formulation.
3.3. Populations to consider in study design
A significant challenge in studying the potential abuse-deterrence of opioid formulations is
the broad range of patients and non-patients who can ingest prescription opioids. It is
possible that a formulation could reduce the likelihood of abuse among patients who take the
drug as prescribed and yet be highly sought by abusers because it can be easily manipulated
into a form that can be administered nasally or by injection. The ideal ADF would provide
effective pain relief with no additional side effects relative to the nonADF medication but
would reduce the risk of abuse among patients using it properly and overdose among both
patients and non-patients who take it.
Another important consideration with many of the potentially abusing populations is the
possibility of an interaction between alcohol and the opioid formulation. A problem with
some long-acting opioid formulations is accelerated absorption (“dose dumping”) when co-
ingested with alcohol, which can produce severe respiratory depression and potentially
death. Given the prevalence of alcohol use by recreational opioid users [54], individuals
with opioid dependence [77], and even pain patients prescribed opioids [4], it is important to
examine interactions with alcohol. The decision regarding whether to exclude subjects with
active or past histories of alcohol abuse from studies of ADFs requires careful consideration
because these individuals will be exposed to opioid formulations that reach the market.
Because of the wide range of individuals who can be affected by opioid ingestion, no single
study can assess all of the at-risk populations, with the possible exception of large-scale
epidemiologic studies. Therefore, it will be necessary for a formulation to undergo testing in
different populations at risk using different research designs.
3.3.1. Young children—The rate of prescription opioid poisoning among young children
has recently been examined [5]. The vast majority of incidents involved opioids prescribed
to a family member, and the rate of incidents correlated with the volume of opioid
analgesics prescribed within the community. Although young children do not typically
abuse opioids, formulations that reduce the appeal to children and which, if ingested, are less
likely to result in harmful outcomes, would be advantageous.
3.3.2. Recreational abusers—The age range and other demographic characteristics of
recreational abusers (i.e., those who take prescription opioids for their euphoric effects) are
broad. An opioid formulation that produces less euphoria in this population would probably
be less likely to be abused, have less street value, and be diverted less frequently. Ideally,
progression from recreational abuse to addiction would be reduced or even eliminated.
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3.3.3. Patients with acute pain—In the absence of significant substance abuse risk
factors, the likelihood of a patient with acute pain who is prescribed opioid analgesics
becoming an opioid abuser is thought to be quite low [23], but there is very little evidence
supporting this belief. Some pain patients do report experiencing euphoria when taking
opioid analgesics for acute pain [6], which raises the possibility that these patients could
develop opioid abuse. Because opioids are commonly prescribed for diverse types of acute
pain, they contribute to the available supply of opioid analgesics used by recreational
abusers and those with addiction. However, most pADFs in development are long-acting
formulations that would be relatively unlikely to be prescribed for acute pain; therefore, the
impact of pADFs on the development of abuse in individuals prescribed opioids for acute
pain, whose risk is already thought to be low, is likely to be minimal.
3.3.4. Patients with chronic pain—Although the percentage of patients with chronic
pain who develop a substance use disorder as a result of medical use of opioids is thought to
be relatively low, evidence of aberrant drug-related behavior, perhaps due to pre-existing
substance abuse, is more common [41,72]; the absolute numbers affected may be
substantial. Given the estimated 116 million people with chronic pain in the United States
alone [22], with many millions more worldwide, even a small decrease in the rate of abuse
could result in substantial public health benefits.
3.3.5. Established opioid addiction—A formulation that resists tampering and
manipulation by those with opioid addiction may have relatively lower demand and thus
would be less likely to be diverted. In addition, the number of clinically significant overdose
events related to such an ADF would likely be low. Although established addiction will not
be eliminated by the existence of ADFs, the total number of individuals abusing prescription
opioids may decline over time or progression to more dangerous routes of administration
may be reduced if an ADF replaces a substantial proportion of prescribed nonADF opioids
within a community.
4. Study design considerations
Several different research designs can help establish the potential abuse deterrence of an
opioid formulation. The main categories of these studies are summarized in Table 2 and are
discussed below.
4.1. Human abuse liability (HAL) assessment
This term is used to describe small, highly controlled studies of the pharmacodynamic
properties of potentially abusable drugs, typically assessed with measures of subjective drug
effects in experienced drug abusers. Whether an opioid formulation is abused appears to
depend on the interplay of at least three factors: (1) the inherent positive characteristics of
the drug (e.g., “likability”), which is related to the time to onset of effects, side effects, and
other properties; (2) formulation factors, including the ease with which the formulation can
be converted into alternate (“preferred”) routes of administration, such as snorting, smoking,
or injecting; and (3) societal factors, such as the availability of the drug relative to
alternatives, peer influences, cost, and stigma [11].
HAL assessment studies can be used to assess and compare the relative likability of different
formulations of a drug. The results of these studies can be used to estimate the likelihood of
abuse of intact and tampered formulations, and such data may also be relevant to the
development of abuse and addiction in patients taking the drug as prescribed. These studies
are useful [37], but favorable data from such studies are not sufficient to demonstrate the
abuse deterrence of a formulation. There are examples of drugs that seem to have less abuse
liability as measured by subjective responses, such as ratings of drug “liking,” and yet self-
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administration of the drug seems discordant with these findings [21]. For example, the
combination of buprenorphine and naloxone has a theoretical basis for abuse deterrence
(injection of the combination should provide naloxone antagonism of the effects of
buprenorphine). This combination has been shown to be less “liked” by intravenous abusers
and to have one-half the street value of buprenorphine alone in Finland [2], but a case series
from Malaysia suggests it might be associated with increased amounts of injection doses,
benzodiazepine injection, and needle sharing [9].
HAL studies can be performed in several ways. A common approach is to use a randomized,
double-blind, placebo-controlled cross-over design studying a relatively small number of
subjects with histories of recreational drug abuse or addiction. Typically, several outcomes
are assessed within four main domains: (1) subjective effects (e.g., likability, street value),
(2) physiological responses (e.g., pupillary constriction, respiratory rate), (3) drug self-
administration behavior (e.g., discrete choice experiments, including drug A vs. drug B or
drug A vs. a monetary choice, for example, $20), and (4) cognitive and psychomotor
performance (e.g., measures quantifying the degree of impairment resulting from drug
intoxication) [45]. Outcome measures are usually repeated to determine the time course of
the effects, such as the time to onset, to peak, and to offset.
Typically, these HAL studies use a positive control, such as a standard formulation opioid,
to assess relative abuse liability, and should show a dose response for the positive control
[17,37]. For a pADF, various doses should be studied, including supra-therapeutic doses if
possible. Ideally testing should include the intact formulation and also the formulation after
it has been tampered and modified in ways likely to be used by prescription opioid abusers
[45].
HAL assessment studies are commonly performed in individuals who are not interested in
obtaining treatment of their abuse but who can be considered “experienced users” with
regard to the intoxicating effects of the class of drugs being examined. Although the specific
characteristics of the subjects enrolled in these studies have varied, individuals with chronic
pain have generally not been included, in part because of difficulties interpreting the data
(e.g., do patients like the opioids because they reduce pain or because they feel high?).
However, conducting these studies in pain patients would potentially provide useful
information about the likely effects of a pADF, particularly if results are compared to results
obtained in non-pain populations. Testing in several different populations could lead to
greater understanding of the level of abuse liability that could be expected in the community.
Several methodologic decisions must be made prior to designing a HAL study. These
include the population that will be studied, the method to be used for administering the
pADF, the outcome measures, and the definition that will be used for detecting a clinically
important reduction in abuse liability. Unfortunately the predictive validity of these studies
has not been systematically examined; this is an area in urgent need of additional research.
Recommendations regarding outcome measures for these studies, based on the best available
evidence, will be presented in a forthcoming IMMPACT manuscript.
4.2. Opioid extractability testing and “kitchen chemistry” studies
Several different types of prescription opioid abusers have been described, in part reflecting
variability in preferences for different opioids and different routes of administration [10,45].
There appears to be an association between the duration of abuse and the likelihood of
progressing from oral ingestion to more “advanced” routes of administration, such as
injection [10]. The creativity and sophistication of abusers’ abilities to convert pADFs into
abusable formulations is well-established [24]. One predictable phenomenon is that abusers
of opioids and those with addiction will attempt to manipulate any new opioid formulation
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in a manner that produces greater euphoria (e.g., nasal inhalation or injection). Formulations
that are resistant to a specific type of tampering can be identified but strategies to
circumvent the deterrent properties are likely to be widely disseminated once such strategies
become known.
In order for a new opioid formulation to be considered an lADF, it would need to be
evaluated in studies designed to determine how readily it can be converted into a form that is
more abusable. Two categories of studies should be performed. These include studies in
controlled laboratory settings, assessing the ease and completeness of extraction of the
opioid using standard measures (e.g., crushing or grinding the pill or capsule or dissolving it
in water or alcohol). Exactly which procedures should be performed on a formulation and
how the ease of extractability should be quantified has been explored elsewhere [46], but
consensus recommendations are needed.
Formulations that appear to be resistant to tampering in controlled laboratory settings can be
characterized further by subjecting them to “kitchen chemistry” studies. In these studies,
opioid abusers have been provided with the formulation and basic kitchen and chemistry
supplies and implements (e.g., razor, hammer, coffee grinder) within a controlled and
observed setting. Whether subjects can extract or convert the opioid into a more desirable
form is then assessed, and the ease (e.g., number of steps involved, complexity of the steps,
time required) and success (e.g., proportion of the opioid that is extracted, desirability of the
extracted opioid) of extraction are determined. For obvious reasons, the results of these
studies are typically not publicly disclosed, but they can be used in determining whether a
product should be further developed.
Since opioid abusers have different preferred routes of administration and different
experience in extracting opioid preparations, studying a variety of different types of abusers
and those with addiction, such as those who snort, smoke, or inject, is important. Several
additional methodological issues must be addressed when designing these studies, such as
the sample size and types of subjects, what basic “supplies” should be available, and how
the results of these studies should be interpreted.
4.3. Analgesic RCTs and their potential role in assessing abuse deterrence
Two critical requirements of any pADF are that the formulation must provide analgesic
efficacy and that it must not produce significant adverse effects beyond those normally
expected in pain patients taking the medication as prescribed. It is possible that a
formulation intended to reduce abuse, such as a pro-drug or agonist-antagonist combination,
would possess less analgesic efficacy than the standard formulation of the same opioid.
Similarly, certain formulations, such as those containing an opioid mixed with a noxious
chemical intended to reduce injection, might produce significant adverse effects within a
population of pain patients. For these reasons, pADFs should be assessed carefully in RCTs
designed to measure analgesic efficacy and adverse events. These trials will be most useful
if they contain at least three arms—placebo, active comparator with equianalgesic dosages
of a standard opioid formulation, and the pADF. The assessment of efficacy and tolerability
of pADFs should adhere to previous recommendations regarding chronic pain clinical trials
[31,32,66,67] to the greatest extent possible.
Traditionally, analgesic RCTs have enrolled a relatively specific and well-defined patient
population, which helps ensure the internal validity of the trial. Patients at high risk for
opioid abuse are generally excluded. However, some of the excluded populations may be
those most likely to derive benefit from a pADF. For this reason, studying both narrow and
broader, more inclusive patient populations in analgesic clinical trials is important.
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4.3.1. Assessing potential abuse—A number of symptoms, behaviors, and outcomes
that suggest the possibility of opioid misuse or abuse within an analgesic RCT may be
assessed retrospectively. These include the presence of certain critical events, such as
euphoria, sedation, and overdose; incidents that are potentially related to opioid abuse, such
as loss or theft of study drug from individuals or study sites; and any evidence of misuse or
abuse, for example, as reported by family members. The rates of each of these potential
indicators of abuse should be compared between different groups, and a systematic analysis
of the reasons for premature terminations from the trial should be performed.
Because retrospectively obtained data are likely to be less comprehensive, sensitive, and
reliable than prospectively designed and assessed outcomes, RCTs examining the analgesic
efficacy of a pADF should also prospectively assess signs of opioid misuse and abuse within
the trial subjects. In addition to defining and capturing the information described above, trial
personnel should be trained to recognize potentially aberrant behaviors. Additional measures
to detect opioid misuse should be collected, including, for instance, urine drug tests and
monitoring for evidence that subjects obtained opioids from other providers, forged
prescriptions, or diverted study medication [41]. Consideration should also be given to
administering standardized opioid risk screening tools, such as the revised Screener and
Opioid Assessment for Patients with Pain [14,19] and instruments designed to detect opioid
misuse, such as the Current Opioid Misuse Measure [13,19,50]. However, the reliability and
validity of such assessments need to be confirmed in large, prospective studies [19,50,68].
4.4. RCTs with misuse or abuse-related outcomes as primary endpoints
One important example of an RCT specifically designed to detect opioid misuse can serve as
a model for how trials can be designed to compare rates of abuse between different opioid
formulations [1]. In this trial, over 11,000 chronic pain patients were assigned to one of
three arms: tramadol (the compound being assessed for abuse risk), randomized treatment
with either tramadol or a non-steroidal anti-inflammatory drug (NSAID) (a control that is
not typically abused), or randomized treatment with either tramadol or a hydrocodone-
containing compound (a control that is sometimes abused). Patients were followed for one
year, during which nine interviews occurred. Opioid misuse was measured using a novel
“Abuse Index” that consisted of scores of 0 or 1 in each of four domains: (1) inappropriate
use (patient must have increased dose on own without physician approval and never skipped
or forgotten a dose); (2) use for purposes other than analgesia (must have two or more of
following: takes more when upset or discouraged, for intoxicated feeling, or for putting
patient in a “good mood”); (3) patient unable to stop use (at least one of following:
physician told patient to stop or cut down, subject tried to stop and found doing so at least
somewhat difficult, or patient believes stopping use would be difficult); and (4) evidence of
opioid withdrawal using a 24-question survey.
In this trial [1], presumptive abuse or dependence was defined as at least two out of the three
criteria if a withdrawal score was not obtained, or three out of four criteria if a withdrawal
score was obtained (a withdrawal score was captured only if patients discontinued their
medication). Following the initial prescription, physicians could prescribe any of the three
options to patients, and analysis was performed according to whichever treatment was taken
at the time of the interview. The rates of presumptive abuse or dependence were similar for
tramadol (2.7%) and NSAIDs (2.5%), but significantly higher for hydrocodone (4.9%).
Strengths of this study include its size, use of both positive and negative controls, and use of
a power analysis to estimate the necessary sample size (though the details of this analysis are
not presented in the manuscript). The rates of abuse or dependence were low in this study;
however, it is possible that urine drug testing or other methods could have detected
additional cases of misuse. Interviewers were trained using structured interviews in the
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detection of signs of abuse and addiction. Critical to the success of obtaining honest
information from patients was the fact that interviewers made it clear that responses would
be kept anonymous to the study physicians. These results should be interpreted with some
caution because physicians were able to change the analgesic prescribed after the initial
assessment, possibly due to pain severity or patient preference, and analgesic outcomes were
not reported.
Features of an RCT of a pADF to evaluate misuse and abuse outcomes in pain patients that
should be considered in the design of the trial include: (1) randomization to pADF, a
comparable standard opioid formulation, placebo, and, if possible, a treatment with known
low abuse potential; (2) use of a representative, diverse population of chronic pain patients,
including patients with histories of abuse; (3) blinding of investigators assessing outcomes,
such as whether a patient is misusing their medication; (4) use of validated measures to
detect misuse, abuse, and addiction; (5) detailed training study personnel to whom patients
will be exposed; (6) evaluation of suspected cases; and (7) comparison of the pain relief and
adverse effects associated with each treatment arm to ensure that reduced abuse liability is
not achieved at the cost of reduced pain relief or increased adverse events.
4.5. Post-marketing epidemiologic studies
Safety, including potential adverse events related to opioid abuse, can be carefully measured
in RCTs, but the information provided is inadequate to evaluate the safety and impact of a
drug in real-world use. Exposure to a drug is tightly controlled in a clinical trial, limiting the
ability to predict what will happen when the drug is introduced into broad usage. As
described, high-risk patients are often excluded from clinical trials, so how they will respond
after the drug is introduced into the market is unknown. The amount of drug to which
patients can be exposed is limited in clinical trials, whereas the dosage and duration of use
may be considerably greater in the community. Importantly, the sample sizes of clinical
trials are small in comparison to the population that may be exposed after the drug is
introduced to the market, so infrequent adverse events can often be detected only after the
drug becomes commercially available. Performing surveillance and epidemiologic studies
during conditions of actual drug use after a drug is approved and becomes widely available
provides invaluable information about its safety and whether a formulation is truly abuse
deterrent. Epidemiologic databases offer the fundamental advantage of recording events
during use, misuse, and abuse of a drug in real life under multiple conditions and by various
types of individuals within large populations. Thus, epidemiologic studies can confirm or
refute, in a naturalistic setting, laboratory assessments of abuse liability.
Post-marketing surveillance, the monitoring of medications and pharmaceutical products or
devices after their release on the market, is required in the United States as well as other
countries. The goal of post-marketing surveillance is to detect adverse events that might not
have been apparent during the review and approval process. In the United States, the Food
and Drug Administration maintains a database to support post-marketing surveillance for all
approved products. The Adverse Event Reporting System (AERS) includes information
obtained through voluntary reporting from health care practitioners and consumers.
Pharmaceutical product manufacturers receive reports of adverse events from the public and
from health care practitioners, which they are required to report to the FDA, and many have
developed reporting systems for this purpose. These databases capture spontaneous reports
by patients, physicians, family members, and manufacturers, among others. Reliance on
spontaneous reports introduces limitations that can only be addressed in comprehensive
pharmacovigilance systems, such as those maintained in a number of European companies.
Post-marketing surveillance is an important tool to identify diversion, abuse, and other
adverse events. In addition to monitoring by the FDA and drug manufacturers, surveillance
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systems have been designed to identify abuse and diversion in multiple populations [12,25].
Several different epidemiological databases and surveillance programs are available for
evaluating misuse of prescription controlled substances in the United States and are
discussed below and in the Appendix.
4.5.1. Limitations of epidemiologic studies—A fundamental challenge in the study of
prescription opioid misuse is acquiring data of sufficient quality and precision to be able to
draw meaningful conclusions. For example, post-marketing surveillance systems for opioid
analgesics must provide sufficient product specificity to allow comparison of different
formulations of the same opioid (e.g., an immediate-release vs. an extended-release
formulation vs. a pADF of the same opioid). It is also important to determine how
individuals are administering a product, such as whether they are taking it orally in intact
form, orally after grinding it, or inhaling, smoking, or injecting it. Ideally, surveillance
systems can also capture basic demographic and clinical information, such as whether the
population using the opioids consists of patients for whom prescription opioid analgesics are
intended. Unfortunately, many data sources are not designed to specifically address the
population of chronic pain patients.
Analysis of real-world data will contain the potential for substantial bias and confounding
due to the uncontrolled design, and bias may be particularly hard to assess in epidemiologic
studies. Comparison of various groups must be interpreted thoughtfully because
unrecognized differences may influence the results. These differences may be present at
baseline or occur in the form of confounders during treatment (e.g., co-morbid diseases or
concomitant medications). It is also difficult to compare databases because of differences in
data collection methodology (e.g., intended purpose, duration, frequency) and definitions of
misuse, abuse, and other variables. For example, misuse of an opioid may be assessed by
collecting acute adverse health events reported to poison control centers, by studying the
diversion of the drug in law enforcement encounters, and by surveying patients under
treatment for opioid dependence or addiction. Examining multiple epidemiological
databases and assessing their agreement (a strategy of “multiple perspectives” or “multiple
detectors”) can partly overcome these challenges, allowing one to better understand the
misuse of a drug.
Studying longitudinal cohorts of drug abusers is an additional method that can provide
detailed information and can address the difficulty in measuring potential confounders
[15,70,75]. It is unlikely that a longitudinal cohort will be nationally representative, but local
cohorts allow changes to be monitored over time as the drug market adapts to a new opioid
formulation and can provide in-depth information about shifts in drug use and consequences
(both intended and unintended).
4.5.2. Surveillance systems and epidemiologic databases used to monitor
prescription drug misuse and abuse in the United States—Many databases have
been used for epidemiologic studies of prescription drug misuse and abuse in the United
States, and each has strengths and limitations. Proper interpretation of their data requires an
understanding of these limitations, which are summarized in the Appendix. Typically, these
databases acquire information when individuals misusing or abusing drugs are forced to
reveal themselves. For example, databases such as the Drug Abuse Warning Network
(DAWN), the National Poison Database, or the poison center component of the Researched
Abuse, Diversion, and Addiction-related Surveillance (RADARS) System acquire data on
persons experiencing health events that prompt someone to contact a poison center or take
them to an emergency department. These systems collect unique information, but are based
on spontaneous reporting; that is, data on the individual is not collected unless someone
contacts a poison control center or goes to an emergency department. Other databases, such
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as the Addiction Severity Index-Multimedia Version, the Opioid Treatment Programs, and
Survey of Key Informant Patients, collect data when a patient enters treatment for substance
abuse. To the extent that these databases capture a representative subset of those entering
substance abuse treatment they can be considered cross-sectional in nature.
Specific limitations of existing databases also depend on the study hypothesis and objective
of the investigation. For example, if information on a specific product is needed (e.g.,
hydrocodone with acetaminophen), systems such as the National Addictions Vigilance
Intervention and Prevention Program and the RADARS System can be useful because they
identify the specific product. Federally funded longitudinal surveillance systems of drug
abuse epidemiology (e.g., Monitoring the Future and the National Survey on Drug Use and
Health) provide population-based estimates of overall abuse and contain little drug-specific
information. The timeliness of data availability is another important consideration. Many
databases release results two or three years after collection, which prevents prompt detection
of changing trends. The geographic specificity of the data also varies between databases. At
times, specific localization of drug misuse activity may be more helpful than national data;
for example, national estimates would not identify the regional hotspots of Appalachia and
the east coast of Florida that have been especially active areas of prescription opioid abuse
and increasing mortality related to prescription drugs, especially opioid analgesics, over the
past few years in the United States. We have highlighted surveillance systems and
epidemiologic databases in the United States for illustrative purposes. Similar systems are
available in other countries with each having their own strengths and limitations.
4.5.3. Other sources of epidemiologic information on pADFs—Several other
sources of information can be useful for assessing the presence and nature of potential
confounders in the cross-sectional data sources described above. We have grouped these
additional data sources into three categories: (1) medical utilization studies examining
administrative claims data; (2) focused studies, including those in localized geographic
areas; and (3) anecdotal sources, such as the internet or news media. Although the
supportive studies described below do not provide strong evidence of abuse-deterrence taken
individually, they can provide complementary information that can inform the interpretation
of studies using the databases described above.
4.5.3.1. Medical utilization studies: Medical utilization studies examining commercial
“sales” data and administrative claims data are necessary to understand how prescription
medications are used in routine medical practice. Samples of commercially available sales
data can be analyzed to estimate how many prescriptions for a drug have been filled and
how many patients have been exposed to the drug in a country or region. These data can be
used in evaluating abuse-deterrence to understand the market penetration of a new
formulation. If there were low sales volume and very little abuse reported, it would be valid
to question if the low abuse rates were due to the inherent nature of the formulation or were
a result of limited utilization. Data from prescription monitoring programs could also be
harnessed for this purpose [47].
Claims data collected during routine medical care by health insurance companies, health
maintenance and managed-care organizations, and publicly-funded health benefit programs
can also be examined. These data are often available for research purposes and can include
patient medical records and pharmacy claims for office and hospital visits, procedures
performed, diagnostic tests, clinical diagnoses, and drugs dispensed. Used widely in
comparative effectiveness research and pharmacoepidemiologic assessments of adverse
events, claims data may provide insight into the medical use of pADFs. In the simplest
analysis, the opioid formulations that patients received could be considered the exposure,
and diagnoses and other outcomes occurring after initiation of treatment related to drug
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abuse could be compared—for example, treatment for substance use disorder or overdose, or
suspicious medication accounting concerns (e.g., repeated early refills). Although relatively
straightforward to conduct, the lack of adjustment for treatment allocation in such a study
makes interpretation of the results particularly problematic.
One of the central limitations with claims data comparing two drugs (e.g., a traditional
opioid and a pADF) is that we do not know the reason why a clinician prescribed one drug
instead of another (or no drug at all), a type of confounding that RCTs avoid through
randomized allocation to treatment conditions. Even without abuse-deterrence labeling,
clinicians may conclude that a drug has abuse-deterrent properties, influenced by the
specifics of the formulation, colleagues’ experiences, and non-regulated information
sources. Patient selection in this manner would be a form of “confounding by indication” if
the outcome to be measured is one related to prescription drug abuse. Put another way, the
same factors that would lead a physician to prescribe a pADF (e.g., substance use history,
psychiatric co-morbidities) are those that would make the individual more likely to
experience the outcome (e.g., patterns of medication use that suggest abuse problems,
overdose).
For this reason, claims data should be used extremely carefully when comparing unadjusted
rates of abuse-related outcomes between opioid formulations. At a minimum, assessments of
exchangeability and adjustment for treatment allocation and confounding by indication are
required, using such approaches as instrumental or latent variables [36], propensity score
matching [43], disease risk scores [3], marginal structural models [33], and other techniques
[40,49], with results supported by sensitivity analyses [38]. Another difficulty with some of
these sources of data is that many of the potential confounders (e.g., drug abuse history) are
not likely to be recorded in clinical charts, possibly requiring external data collection to
assess the nature and degree of confounding prior to adjustment [62]. Additionally, those
who are abusing their medications may pay out-of-pocket to fill some or all of their
prescriptions and therefore avoid having the extent of their use captured in the claims data.
The other major limitation of claims data is that abuse-related outcomes are relatively rarely
identified in the claims data and have not been externally validated, with limited
understanding of the extent and nature of misclassification (but see [74]).
Claims-based studies do have the potential to provide contextual information on the medical
use of a pADF prior to conducting causal modeling. For example, when a pADF is first
marketed, only specialists may prescribe it or the drug may be prescribed to an inherently
different patient population (in terms of demographic or underlying disease characteristics)
than those receiving the traditional formulation. Health insurance plans may place a pADF
on restricted formularies due to cost, and those who receive the pADF may be individuals
who have had to demonstrate eligibility criteria; alternatively, some third-party payers may
not cover or may place barriers (such as prior authorization) that limit access of individuals
with certain types of coverage to a pADF. In either of these cases, the population that
receives the pADF will differ in important ways from the eligible treatment population, and
interpretation of the data will require an understanding of these potential confounders. These
are hypothetical scenarios that can be informed by analyzing claims data because the
purpose of these studies is not necessarily to make a causal inference, but rather to
understand the nature of the medical use.
4.5.3.2. Focused studies: Focused studies or rapid assessments can be conducted in a
limited geographic area (e.g., city or county, a large hospital or nursing home), leveraging
researchers’ existing connections with a community. Focused studies may enroll fewer
participants than the national data systems, but they allow for more in-depth questioning
about reasons for using or not using a pADF and can provide information about an
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individual’s history and allow for follow-up of a cohort as market shifts occur. These studies
may be easier, less expensive, and faster to conduct compared with large national cross-
sectional studies. Although the generalizability of the results of focused studies can be
questioned, a great deal has been learned from cohorts of injecting drug users and persons
with opioid addiction [7,16,53,56,57,60].
In order to provide credibility to observations made using large national databases, it is
essential to simultaneously monitor conditions in the broader illicit market of prescription
opioids and illicitly manufactured opioids for potentially confounding influences. For
example, a sustained increase in the availability of cheap refined heroin may lead to a
decrease in the desirability of all prescription opioids among nonmedical users. In the
opposite circumstance, sudden decreases in heroin or “black-market” prescription opioid
availability may create conditions where individuals are willing to use whatever opioid is
available, even if they are ADFs or formulations that would be less desirable when more
choices are available. In these cases, the relative rates of abuse may be due to the social
environment in which the drugs are consumed rather than the inherent nature of the
formulation. Supply limitations are often geographically localized, but if they occur in
enough places, they may influence national data. Indeed, efforts are underway to cause
exactly this kind of shift in the illicit market for prescription controlled substances, such as
through expanded use of prescription monitoring programs in the United States. Assessing
these external forces is critical to understanding whether population-level changes in
patterns of abuse may be attributable to new opioid formulations rather than to changes in
the availability of other opioids.
Surveys of active drug users are also important for understanding potential safety concerns
arising from methods to circumvent abuse-deterrent mechanisms. The “abuse-deterrent”
formulation of temazepam in the United Kingdom in the 1990s and Australia in the 2000s
offers a graphic example of unintended consequences associated with circumventing ADFs
that led to greater morbidity among injecting drug users. Although the formulation was
intended to reduce injection misuse, it apparently did not do so, but it did appear to be
responsible for an increased rate of injection site complications [8,27,29,30,58,59,61]. For
formulations intended to deter crushing and injecting, participants recruited from syringe
exchange programs and drug treatment programs may offer considerable insight into the
perception of new opioid formulations in the addiction community [27].
4.5.3.3. Anecdotal reports: Anecdotal reports are likely to play a role in the initial
perception of the effectiveness of a pADF once it enters the market. Lags in data collection
and publication time for major national data sources create a vacuum for information that
will naturally be filled by anecdotal reports.
Anecdotal information is not formally considered in most plans for the evaluation of pADFs,
but nevertheless shapes public opinion and should be monitored because of the wealth of
data it may provide and for hypothesis generation. For example, internet postings about
prescription medications from drug abusers have been considered in FDA Advisory
Committee meetings [69], suggesting that anecdote might play a role in medical decision
making. Initial reactions after a drug is launched among drug users and pain patients can
provide clues regarding how consumers perceive the drug, and internet postings in drug user
forums and news media reports can be early warning signs for safety signals associated with
new medications [26], such as the consequences of tampering with a pADF. Similarly, blogs
and internet forums for pain patients may suggest that an opioid formulation has previously
undocumented benefits or harms that can be studied formally. Taken together, the power of
anecdotal reports lies in the ease of reporting and their ability to be quickly disseminated; as
electronic communication and social media continue to expand, text-based anecdotal reports
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from consumers are likely to play an increasing role in evaluation, with reasonable
expectation that these sources be monitored.
5. Conclusions
Opioid analgesics are essential to the management of pain in many patients, but opioids,
particularly higher dose formulations, are also associated with significant risk of abuse,
overdose, and mortality. Due to the many types of individuals who may be exposed to
opioids, an opioid formulation will need to be studied in different populations using a
mosaic of different study designs to evaluate its abuse-deterrent properties. To demonstrate
abuse deterrence comprehensively, a formulation would ideally need to: (1) show abuse
deterrence in a set of studies in non-pain patients, patients with acute pain, and patients with
chronic pain, as described above, and (2) show a lower than expected rate of abuse and
overdose in epidemiologic surveillance studies making use of complementary databases
such as those discussed. Of course, epidemiologic data can only be generated after a
formulation has been introduced into the general population, so some of these data cannot be
generated prior to drug approval by regulatory agencies.
Table 3 provides a summary of the recommendations we have discussed throughout this
article. It is unlikely that a pADF will show measurable benefits in all populations studied
and using all of the different research designs we have discussed. Relative judgments of the
clinical and social importance of the benefits will likely be necessary; for example, a pADF
that reduces the ease of an opioid being ground up and injected will not eliminate all abuse
of the drug, nor will it be likely to benefit any but the most high-risk patients. At the same
time, incremental reductions in the risk of overdose, hepatitis, HIV, and death among
intravenous drug abusers would be meaningful.
Once an ADF is developed, its cost will be an important consideration. The value of ADFs
to patients and to society will depend directly on the cost of the drugs and the degree to
which they are used. An expensive ADF may be worse for pain patients because some of the
cost will likely be passed on to them and high cost may impair access to pain medication.
Intravenous opioid abusers will likely revert to other opioid formulations, including heroin,
and therefore not truly benefit from a reduced risk of overdose from an ADF. Whether the
societal value derived from modest reductions in the rates of relatively uncommon events
justifies increased costs resulting from the use of pADFs in pain patients will be difficult to
determine. Nevertheless, the ongoing epidemic of prescription opioid abuse requires the
development of strategies to curtail abuse while providing pain medications to those who
need it, and ADFs are likely to remain a key strategy in the future.
A number of important limitations of the available literature are described above. Research
is needed to evaluate the ability of HAL studies to predict real world abuse. In addition,
careful assessment of misuse, abuse, and diversion using validated instruments should be
embedded in analgesic clinical trials assessing new opioid formulations.
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Table 1
Examples of different types of putative abuse deterrent formulations of opioids
Formulation mechanism Mechanism of deterrence Potential advantages Potential disadvantages
Physical barrier Resists conversion into
alternative forms (e.g., barrier
that impedes crushing or
dissolving)
May reduce likelihood opioid can be
converted into a form that can be
snorted or injected
Difficult to prevent conversion into
all forms that could be abused;
potential that certain barriers might
reduce ease of use for patients
Chemical additives
 Opioid antagonist (e.g.,
 naloxone)
Counteract opioid effects if oral
route bypassed (oral ingestion
of antagonist is poorly
absorbed)
May reduce non-oral administration Potential for reduced analgesic
efficacy
 Irritant (e.g., capsaicin
 or niacin)
Produces noxious reaction if
oral route bypassed or
excessive dosage taken
May reduce likelihood of use of
excessive dosage
Potential for noxious effects
among non-abusers; possible
ceiling dosage for patients
Prodrug a Requires conversion of opioid
into active form in
gastrointestinal tract
Specifically targets non-oral route of
use, might reduce likelihood of
overdose with excessive oral dosage
(if conversion mechanisms are
overwhelmed)
Potential for reduced analgesic
efficacy; possible ceiling dosage
for patients (if conversion
mechanisms are overwhelmed)
a
Regulatory agencies may consider a prodrug to be a “new molecular entity” subject to its own controlled substances scheduling rather than a new
formulation of an existing drug.
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Table 2
Categories of clinical studies that can be used to assess the potential for reduction in abuse of putative abuse-
deterrent formulations
















Can suggest the likelihood that
intact




patients studied with intact
formulation
only; may not predict real
world abuse
“Kitchen chemistry” To predict the
likelihood and
methods by which





access to the drug and
basic tools (e.g., for
grinding or shaving or
dissolving) to
elucidate the ease of
manipulation of the
drug
May provide useful information
about
how a drug may be manipulated
by
opioid addicts
Artificial setting; may not
uncover methods
of manipulation that would be
discovered
and disseminated in the
community

















excluding the highest risk
patients;
probably not very sensitive to
detecting
abuse or misuse. Could be
improved by
the inclusion of more
representative
samples





abuse as a primary
outcome
May be best method of
determining
relative likelihood of abuse in
pain
patients
May need very large sample
sizes
depending on risk level of
population and







Epidemiology To estimate within
a population









Best evidence that a formulation
is
having intended effects on all





(e.g., highest risk patients
most likely to be
prescribed the abuse deterrent
formulation); requires
significant
population usage to detect
signal; requires
monitoring over long time
intervals; quality
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Table 3
Recommendations for clinical research to evaluate abuse-deterrent formulations of opioid analgesics
1 Adopt standard definitions of misuse, abuse, and addiction
2 Conduct studies assessing:
• Abuse liability, for example, in recreational substance abusers
• The likelihood that opioid abusers will find methods to circumvent the deterrent properties of the formulation
• Misuse and abuse outcomes within randomized clinical trials enrolling low risk and high risk of abuse pain patients
• Post-marketing epidemiologic data
3 Features of a randomized clinical trial of a putative abuse-deterrent formulation (pADF) to evaluate misuse and abuse outcomes in
pain patients that should be considered in the design of the trial include:
• Randomization to pADF, equianalgesic dosages of a comparable standard opioid formulation, placebo, and, if possible,
a treatment with known low abuse potential; if no standard formulation exists, such as with a new molecular entity,
consider comparisons with a well-characterized mu-opioid receptor agonist at what are expected to be equianalgesic
dosages
• Use of a representative, diverse population of pain patients, including high risk patients with histories of abuse
• Prospective assessments of signs and symptoms of opioid misuse and abuse
• Trial personnel should be carefully trained to recognize potentially aberrant behaviors
• Blinding of investigators assessing outcomes
• Use of validated questionnaires and other measures to detect misuse, abuse, and addiction (e.g., urine drug screening)
• Clinical evaluation of potential cases
• Careful evaluation of pain relief in the different treatment groups to ensure that reduced abuse liability is not achieved at
the cost of reduced pain relief
• Reasons for premature terminations from the trial should also be carefully evaluated.
4 Post-marketing surveillance should be used to examine misuse, abuse, addiction, diversion, and other adverse outcomes
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